Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 601–700 of 4,275
Cellular senescence and cancer chemotherapy resistance
Gordon, R. R., & Nelson, P. S. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.002 · Cited by 134
“Comprehensive studies of transcriptional responses to genotoxic stress induced by cancer therapeutics have identified a spectrum of highly-induced secreted proteins originating in the tumor microenvironment that comprise several hundred factors (Bavik et al., 2006; Coppe et al., 2008; Kuilman et al., 2008).”
BackgroundInfluentialSelf-citationCellular senescence links aging and diabetes in cardiovascular disease
Shakeri, H., Lemmens, K., Gevaert, A. B., De Meyer, G. R. Y., & Segers, V. F. M. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00287.2018 · Cited by 134
“●Regulation of SASP Interleukin-8 ●Paracrine effect of cellular senescence (30, 100) ●Atherosclerosis (173) ●Overexpression in diabetic conditions (127) ●Cancer growth inhibition (191) ●Wound healing (107) NF- B ●Direct cause of senescence (90) ●Chronic inflammation ●Diabetic cardiomyopathy (115, 202) ●Cancer growth i…”
BackgroundSecher, T., Samba-Louaka, A., Oswald, E., & Nougayrède, J.-P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077157 · Cited by 132
“In addition, we demonstrated that SASP includes factors that are known to be associated with aggressive cancer cells [12,54], including IL-6 and MMP which can induce epithelial cell invasion or direct tumour promoting effects respectively [56].”
Yang, R., Chen, J., Zhang, J., Qin, R., Wang, R., Qiu, Y., Mao, Z., Goltzman, D., & Miao, D. (2020) · Aging Cell · doi:10.1111/acel.13095 · Cited by 133
“We recently demonstrated that the aging induced by 1,25(OH)2D deficiency was accompanied by increased cellular senescence and SASP in multiple organs, whereas exogenous 1,25(OH)2D3 supplementation could largely rescue the F I G U R E 3 Supplementation of exogenous 1,25(OH)2D3 prevents bone aging induced by natural agi…”
BackgroundInfluentialCarroll, J. E., Cole, S. W., Seeman, T. E., Breen, E. C., Witarama, T., Arevalo, J. M. G., Ma, J., & Irwin, M. R. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.08.024 · Cited by 129
“Further selection was made of additional individual genes important in signaling senescence and initiating the inflammatory cytokine response after DDR: ATM, NBS1 (NBN), and CHK2 Coppé et al., 2008; Rodier et al., 2009.”
InfluentialRole of genomic instability in arsenic-induced carcinogenicity. A review
Bhattacharjee, P., Banerjee, M., & Giri, A. K. (2013) · Environment International · doi:10.1016/j.envint.2012.12.004 · Cited by 150
“Whereas senescent cells are beneficial by arresting abnormal cellular proliferation early in life, their continuous accumulation might alter cellular microenvironment by secreting a wide range of inflammatory intermediates and proteases and thus leading to aging, and ironically, might result in late-life cancer (Campi…”
BackgroundSpyridopoulos, I., Martin‐Ruiz, C., Hilkens, C., Yadegarfar, M. E., Isaacs, J., Jagger, C., Kirkwood, T., & von Zglinicki, T. (2016) · Aging Cell · doi:10.1111/acel.12430 · Cited by 133
Secretion of leukotrienes by senescent lung fibroblasts promotes pulmonary fibrosis
Wiley, C. D., Brumwell, A. N., Davis, S. S., Jackson, J. R., Valdovinos, A., Calhoun, C., Alimirah, F., Castellanos, C. A., Ruan, R., Wei, Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130056 · Cited by 132
“Thus far, the SASP has been defined as a complex set of secreted proteins that are variable depending on the cell type and driver of senescence (10, 16, 45).”
BackgroundSelf-citationThe potential role of necroptosis in inflammaging and aging
Royce, G. H., Brown‐Borg, H. M., & Deepa, S. S. (2019) · GeroScience · doi:10.1007/s11357-019-00131-w · Cited by 146
“Senescent cells exhibit a secretory phenotype, characterized by the secretion of numerous proinflammatory cytokines (termed the senescence-associated secretory phenotype or SASP), which can alter the function of nearby normal cells (Coppé et al. 2008, 2010).”
BackgroundHodes, R. J., Sierra, F., Austad, S. N., Epel, E., Neigh, G. N., Erlandson, K. M., Schafer, M. J., LeBrasseur, N. K., Wiley, C., Campisi, J., et al. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13299 · Cited by 132
Self-citationTchkonia, T., Palmer, A. K., & Kirkland, J. L. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa728 · Cited by 129
Lafargue, A., Degorre, C., Corre, I., Alves-Guerra, M.-C., Gaugler, M.-H., Vallette, F., Pecqueur, C., & Paris, F. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.04.019 · Cited by 131
“histone, cell cycle modulator Chk1 and Chk2 proteins and p53 [10].”
BackgroundThe atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence
Aksoy, O., Chicas, A., Zeng, T., Zhao, Z., McCurrach, M., Wang, X., & Lowe, S. W. (2012) · Genes & Development · doi:10.1101/gad.196238.112 · Cited by 130
“…senescent cells secrete factors that modulate their microenvironment and trigger immune surveillance, and these processes may contribute to the tumor-suppressive properties of the program in a non-cell-autonomous manner (Campisi and d’Adda di Fagagna 2007; Coppe et al. 2008; Kuilman et al. 2008).”
BackgroundLoss of lamin B1 is a biomarker to quantify cellular senescence in photoaged skin
Wang, A. S., Ong, P. F., Chojnowski, A., Clavel, C., & Dreesen, O. (2017) · Scientific Reports · doi:10.1038/s41598-017-15901-9 · Cited by 131
Gonzalez-Meljem, J. M., Haston, S., Carreno, G., Apps, J. R., Pozzi, S., Stache, C., Kaushal, G., Virasami, A., Panousopoulos, L., Mousavy-Gharavy, S. N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01992-5 · Cited by 130
Calcium signaling and cellular senescence
Martin, N., & Bernard, D. (2017) · Cell Calcium · doi:10.1016/j.ceca.2017.04.001 · Cited by 138
Shahbandi, A., Rao, S. G., Anderson, A. Y., Frey, W. D., Olayiwola, J. O., Ungerleider, N., & Jackson, J. G. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0564-6 · Cited by 143
Tumor cell senescence response produces aggressive variants
Yang, L., Fang, J., & Chen, J. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2017.49 · Cited by 131
Menon, R., Behnia, F., Polettini, J., & Richardson, L. (2020) · Seminars in Immunopathology · doi:10.1007/s00281-020-00808-x · Cited by 140
Cellular Interactions in the Tumor Microenvironment: The Role of Secretome
da Cunha, B. R., Domingos, C., Stefanini, A. C. B., Henrique, T., Polachini, G. M., Castelo‐Branco, P., & Tajara, E. H. (2019) · Journal of Cancer · doi:10.7150/jca.21780 · Cited by 140
“In addition, these factors [66, 72] may promote the formation of tumors in vivo and confer metastatic properties [73, 74].”
BackgroundMechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease
Welch, G., & Tsai, L. (2022) · The EMBO Reports · doi:10.15252/embr.202154217 · Cited by 129
Targeting Senescent Cells for a Healthier Aging: Challenges and Opportunities
Song, S., Tchkonia, T., Jiang, J., Kirkland, J. L., & Sun, Y. (2020) · Advanced Science · doi:10.1002/advs.202002611 · Cited by 129
Sharma, A. K., Roberts, R. L., Benson, R. D., Pierce, J. L., Yu, K., Hamrick, M. W., & McGee-Lawrence, M. E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00354 · Cited by 131
Lesina, M., Wörmann, S. M., Morton, J., Diakopoulos, K. N., Korneeva, O., Wimmer, M., Einwächter, H., Sperveslage, J., Demir, I. E., Kehl, T., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86477 · Cited by 128
MiRNA in innate immune responses: novel players in wound inflammation
Roy, S., & Sen, C. K. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00160.2010 · Cited by 127
Biology of Cancer and Aging: A Complex Association With Cellular Senescence
Falandry, C., Bonnefoy, M., Freyer, G., & Gilson, E. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1432 · Cited by 128
Replicatively senescent cells are arrested in G1 and G2 phases
Mao, Z., Ke, Z., Gorbunova, V., & Seluanov, A. (2012) · Aging · doi:10.18632/aging.100467 · Cited by 128
“Senescent cells were later found to affect surrounding cells by secreting inflammatory cytokines [2] and were recently shown to promote agerelated pathology in vivo [3].”
BackgroundMaciel-Barón, L. A., Morales-Rosales, S. L., Aquino-Cruz, A. A., Triana-Martínez, F., Galván-Arzate, S., Luna-López, A., González-Puertos, V. Y., López-Díazguerrero, N. E., Torres, C., & Königsberg, M. (2016) · AGE · doi:10.1007/s11357-016-9886-1 · Cited by 128
The Fountain of Youth by Targeting Senescent Cells?
de Keizer, P. L. J. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.11.006 · Cited by 127
Targeting senescent cells: approaches, opportunities, challenges
von Kobbe, C. (2019) · Aging · doi:10.18632/aging.102557 · Cited by 127
“Another important characteristic is the regulated secretion of interleukins (ILs), inflammatory factors, termed the senescenceassociated secretory phenotype (SASP) [3].”
BackgroundInfluentialCindrova-Davies, T., Fogarty, N. M. E., Jones, C. J. P., Kingdom, J., & Burton, G. J. (2018) · Placenta · doi:10.1016/j.placenta.2018.06.307 · Cited by 127
Kumar, M., Seeger, W., & Voswinckel, R. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0382ps · Cited by 127
“324 American Journal of Respiratory Cell and Molecular Biology Volume 51 Number 3 | September 2014 epithelial cells depends largely on the composition of the culture medium used and on the use of feeder layers (24–26).”
BackgroundInfluentialOxidative Stress in Cells with Extra Centrosomes Drives Non-Cell-Autonomous Invasion
Arnandis, T., Monteiro, P., Adams, S. D., Bridgeman, V. L., Rajeeve, V., Gadaleta, E., Marzec, J., Chelala, C., Malanchi, I., Cutillas, P. R., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.10.026 · Cited by 129
“Centrosome Amplification Induces an Early Stress Response that Leads to Altered Secretion Altered protein secretion in senescent cells, known as the senescence-associated secretory phenotype (SASP), was previously shown to lead to IL-8 secretion (Coppe et al., 2008).”
BackgroundMethodCauses of and Molecular Targets for the Treatment of Intervertebral Disc Degeneration: A Review
Ohnishi, T., Iwasaki, N., & Sudo, H. (2022) · Cells · doi:10.3390/cells11030394 · Cited by 135
“Accumulation of senescent cells invokes senescence-associated secretory phenotype that exhibits chronic inflammation and induces degradation of the disc matrix [18,19].”
BackgroundCell Autonomous and non-autonomous effects of senescent cells in the skin
Demaria, M., Desprez, P. Y., Campisi, J., & Velarde, M. C. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.108 · Cited by 127
“Notably, this phenotype can be rescued in senescence-free mice by topical application of the SASP factor platelet-derived growth factor AA, which promotes the differentiation and maturation of myofibroblasts.”
BackgroundInfluentialThe DNA Damage Response in Neurons: Die by Apoptosis or Survive in a Senescence-Like State?
Fielder, E., von Zglinicki, T., & Jurk, D. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161221 · Cited by 126
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?
Carpenter, V. J., Saleh, T., & Gewirtz, D. A. (2021) · Cancers · doi:10.3390/cancers13040723 · Cited by 124
“The mRNA profiles of senescent cells are remarkably different from their proliferating or quiescent counterparts [13]; however, these senescence-associated transcriptional profiles are also heterogenous among senescent cells [15].”
BackgroundMajor depression and the biological hallmarks of aging
Lorenzo, E. C., Kuchel, G. A., Kuo, C., Moffitt, T. E., & Diniz, B. S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101805 · Cited by 145
Boyajian, J. L., Ghebretatios, M., Schaly, S., Islam, P., & Prakash, S. (2021) · Nutrients · doi:10.3390/nu13124550 · Cited by 115
“specifically through functional loss of the tumor suppression protein p53 [87].”
BackgroundCurrent Understanding of Autophagy in Pregnancy
Nakashima, A., Tsuda, S., Kusabiraki, T., Aoki, A., Ushijima, A., Shima, T., Cheng, S., Sharma, S., & Saito, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092342 · Cited by 144
“Abbreviations Atg Autophagy-related BECN1 Beclin 1 CMA Chaperone-mediated autophagy DOHaD Developmental origins of health and disease ER Endoplasmic reticulum E2 17β-estradiol EVTs Extravillous trophoblasts FIP200 FAK family kinase-interacting protein of 200 kDa FGR Fetal growth restriction GABARAP Gamma-aminobutyric…”
BackgroundBredeson, S., Papaconstantinou, J., Deford, J. H., Kechichian, T., Syed, T. A., Saade, G. R., & Menon, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113799 · Cited by 124
“After obtaining the data on Pp38 MAPK activation and cytokines (especially IL-6 and IL-8 that are also senescence related [34, 35], we verified the association between the production of these cytokines and senescence development in fetal membranes.”
MethodRole of hypoxia in cellular senescence
Gao, H., Nepovimová, E., Heger, Z., Valko, M., Wu, Q., Kuča, K., & Adam, V. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106841 · Cited by 145
Murakami, T., Inagaki, N., & Kondoh, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.869414 · Cited by 152
“On the other hand, senescent cells also show enhanced secretion of proinflammatory cytokines and chemokines with activation of the nuclear factor-kappa B (NFkB) pathway (29), resulting in what is known as a senescenceassociated secretory phenotype (SASP) (30).”
BackgroundAge- and tissue-specific expression of senescence biomarkers in mice.
Hudgins, A. D., Tazearslan, C., Tare, A., Zhu, Y., Huffman, D., & Suh, Y. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00059 · Cited by 124
“The expression of Il6, a major proinflammatory cytokine of the SASP (Coppe et al., 2008, 2010b), did not significantly increase with age in any tissue, although there was a trend toward increased expression observed (Figure 1).”
BackgroundTargeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance
Chen, F., Long, Q., Fu, D., Zhu, D., Ji, Y., Han, L., Zhang, B., Xu, Q., Liu, B., Li, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06860-4 · Cited by 122
Self-citationChibaya, L., Murphy, K. C., DeMarco, K. D., Gopalan, S., Liu, H., Parikh, C. N., Lopez-Diaz, Y., Faulkner, M., Li, J., Morris, J. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00553-8 · Cited by 152
“SMA depletion in vivo KPC1 PDAC cells (5 × 10(4)) were transplanted orthotopically into 8- to 16-week-old SMA-TK male (27) and female (18) mice.”
MethodSimvastatin suppresses breast cancer cell proliferation induced by senescent cells
Liu, S., Uppal, H., Demaria, M., Desprez, P.-Y., Campisi, J., & Kapahi, P. (2015) · Scientific Reports · doi:10.1038/srep17895 · Cited by 124
Self-citationSmall-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype
Wiley, C. D., Schaum, N., Alimirah, F., Lopez-Dominguez, J. A., Orjalo, A. V., Scott, G., Desprez, P.-Y., Benz, C., Davalos, A. R., & Campisi, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-20000-4 · Cited by 124
mTOR Signaling from Cellular Senescence to Organismal Aging
Xu, S. (2014) · Aging and Disease · doi:10.14336/ad.2014.0500263 · Cited by 124
“Matrix metalloproteinases (MMPs), which are prominent SASP components, can disrupt alveolar morphogenesis, differentiation and branching of mammalian breast epithelial cells [84].”
InfluentialSenescent Carcinoma-Associated Fibroblasts Upregulate IL8 to Enhance Prometastatic Phenotypes
Wang, T., Notta, F., Navab, R., Joseph, J., Ibrahimov, E., Xu, J., Zhu, C.-Q., Borgida, A., Gallinger, S., & Tsao, M.-S. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0192 · Cited by 123
“Cell lines, tissue, and mouse strains This study was approved by the Research Ethics Board of the UniversityHealthNetwork (13-6377).”
BackgroundMethodThe lysosomal proteome of senescent cells contributes to the senescence secretome
Rovira, M., Sereda, R., Pladevall‐Morera, D., Ramponi, V., Marín, I., Maus, M., Madrigal‐Matute, J., Díaz, A., García, F., Muñoz, J., et al. (2022) · Aging Cell · doi:10.1111/acel.13707 · Cited by 146
Farr, J. N., Rowsey, J. L., Eckhardt, B. A., Thicke, B. S., Fraser, D. G., Tchkonia, T., Kirkland, J. L., Monroe, D. G., & Khosla, S. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3729 · Cited by 122
Fard, M. T., & Stough, C. K. K. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00056 · Cited by 132
SenNet Consortium, Writing Group, Lee, P. J., Benz, C. C., Blood, P., Börner, K., Campisi, J., Chen, F., Daldrup-Link, H., De Jager, P., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00326-5 · Cited by 122
Self-citationKang, C. (2019) · PubMed · doi:10.14348/molcells.2019.0298 · Cited by 121
Ali, D., Tencerova, M., Figeac, F., Kassem, M., & Jafari, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.981487 · Cited by 122
Aging-dependent regulatory cells emerge in subcutaneous fat to inhibit adipogenesis
Nguyen, H. P., Lin, F., Yi, D., Xie, Y., Dinh, J., Xue, P., & Sul, H. S. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.03.026 · Cited by 121
Stressing the cell cycle in senescence and aging
Chandler, H., & Peters, G. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.07.005 · Cited by 119
Rheumatoid Arthritis: A Role for Immunosenescence?
Lindstrom, T. M., & Robinson, W. H. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02965.x · Cited by 121
“In contrast, senescence of fibroblast and epithelial cells is associated with a change in the secretory profile of these cells, involving an increase in secretion of multiple growth factors, adhesion molecules, and proinflammatory cytokines, including IL-6.(85) In addition, aging is associated with low-grade inflammat…”
BackgroundCellular senescence, senescence-associated secretory phenotype, and chronic kidney disease
Wang, W.-J., Cai, G.-Y., & Chen, X.-M. (2017) · Oncotarget · doi:10.18632/oncotarget.17327 · Cited by 121
Burton, D. G. A., Matsubara, H., & Ikeda, K. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.07.005 · Cited by 121
Cellular senescence in lung cancer: Molecular mechanisms and therapeutic interventions
Jha, S. K., Rubis, G. D., Devkota, S. R., Zhang, Y., Adhikari, R., Jha, L. A., Bhattacharya, K., Mehndiratta, S., Gupta, G., Singh, S. K., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102315 · Cited by 149
“…genes have been identified (Hernandez-Segura et al., 2019), the senescent transcriptome and proteome is dynamic and varied, depending on the tissue from which cells origin and on the specific stimulus that induced senescence (Coppe et al., 2008; Domen et al., 2022b; Hernandez-Segura et al., 2019).”
SIRT1 as a therapeutic target in inflammaging of the pulmonary disease
Rahman, I., Kinnula, V. L., Gorbunova, V., & Yao, H. (2012) · Preventive Medicine · doi:10.1016/j.ypmed.2011.11.014 · Cited by 120
Intercellular communication of cellular stress monitored by γ-H2AX induction
Dickey, J. S., Baird, B. J., Redon, C. E., Sokolov, M. V., Sedelnikova, O. A., & Bonner, W. M. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp192 · Cited by 119
“Recent work indicates, in fact, that senescent and genetically unstable cells may also transmit DNA damaging bystander signals [44,45].”
BackgroundRoles and mechanisms of cellular senescence in regulation of tissue homeostasis
Ohtani, N., & Hara, E. (2013) · Cancer Science · doi:10.1111/cas.12118 · Cited by 119
Ionizing Radiation-Induced Responses in Human Cells with Differing TP53 Status
Mirzayans, R., Andrais, B., Scott, A., Wang, Y., & Murray, D. L. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122409 · Cited by 135
“However, as mentioned earlier, cells undergoing SIPS secrete myriad factors that can promote cell growth and invasiveness, as well as angiogenesis [13,112].”
BackgroundThe Link Between Inflammaging and Degenerative Joint Diseases
Rezuş, E., Cardoneanu, A., Burlui, A., Luca, A., Codreanu, C., Tamba, B.-I., Stanciu, G. D., Dima, N., Badescu, C. M., & Rezuș, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030614 · Cited by 129
p53 and the Carcinogenicity of Chronic Inflammation
Gudkov, A. V., & Komarova, E. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026161 · Cited by 132
“The proposed model accommodates Judy Campisi’s hypothesis linking aging with the SASP of accumulating senescent cells (Coppe et al. 2008), indications of a general decline in p53 function in aging tissues (Feng et al.”
BackgroundTao, J., Li, S., Gan, R.-Y., Zhao, C.-N., Meng, X., & Li, H.-B. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1555789 · Cited by 119
“The DCA circulation in liver has been proven to provoke senescence-associated secretory phenotype in hepatic stellate cells, producing inflammatory and cancer-promoting factors (Coppe et al. 2008; Friedman 2008; Kuilman and Peeper 2009).”
BackgroundIonizing radiation-induced cellular senescence promotes tissue fibrosis after radiotherapy. A review
Nguyen, H. Q., To, N. H., Zadigue, P., Kerbrat, S., De La Taille, A., Le Gouvello, S., & Belkacemi, Y. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.012 · Cited by 120
Lau, L., Porciuncula, A., Yu, A., Iwakura, Y., & David, G. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00586-18 · Cited by 119
“IL-6 and IL-8 are secreted at very high levels during senescence in most cell types and make up a major portion of the SASP (20, 26, 36).”
BackgroundSenescent stroma promotes prostate cancer progression: The role of miR‐210
Taddei, M. L., Cavallini, L., Comito, G., Giannoni, E., Folini, M., Marini, A., Gandellini, P., Morandi, A., Pintus, G., Raspollini, M. R., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.009 · Cited by 119
“In keeping with this idea, hypoxia synergizes with both tumor progression due to CAFs contact (Comito et al., 2012) and with senescence of fibroblasts (Coppe et al., 2008).”
BackgroundMethodPeng, X., Wu, Y., Brouwer, U., van Vliet, T., Wang, B., Demaria, M., Barazzuol, L., & Coppes, R. P. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03074-9 · Cited by 119
Del Rey, M. J., Valín, Á., Usategui, A., Ergueta, S., Martín, E., Municio, C., Cañete, J. D., Blanco, F. J., Criado, G., & Pablos, J. L. (2019) · Immunity & Ageing · doi:10.1186/s12979-019-0169-4 · Cited by 119
From DNA damage to mutations: All roads lead to aging
Vijg, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101316 · Cited by 119
Mechanisms and significance of therapy-induced and spontaneous senescence of cancer cells
Mikuła-Pietrasik, J., Niklas, A., Uruski, P., Tykarski, A., & Książek, K. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03261-8 · Cited by 119
Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin
Miao, L., Wang, Y., Lin, C. M., Xiong, Y., Chen, N., Zhang, L., Kim, W. Y., & Huang, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.027 · Cited by 118
Blagosklonny, M. V. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.506 · Cited by 116
Belle, J. I., Sen, D., Baer, J. M., Liu, X., Lander, V. E., Ye, J., Sells, B. E., Knolhoff, B. L., Ahmad, F. F., Kang, L., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0428 · Cited by 136
Kim, C., Kang, D., Lee, E. K., & Lee, J. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/2062384 · Cited by 125
Kim, J., Gee, H. Y., & Lee, M. G. (2018) · Journal of Cell Science · doi:10.1242/jcs.213686 · Cited by 118
Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.019 · Cited by 114
Block, T. J., Marinkovic, M., Tran, O. N., Gonzalez, A. O., Marshall, A., Dean, D. D., & Chen, X.-D. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0688-x · Cited by 118
Senotherapeutic drugs for human intervertebral disc degeneration and low back pain
Cherif, H., Bisson, D. G., Mannarino, M., Rabau, O., Ouellet, J. A., & Haglund, L. (2020) · eLife · doi:10.7554/elife.54693 · Cited by 132
“Senescent cells secrete a range of cytokines, chemokines, growth factors, and proteases termed as the senescence-associated secretory phenotype (SASP) (Herbig et al., 2006; Kuilman et al., 2008; Coppé et al., 2008; Xu et al., 2015).”
BackgroundOf Flies, Mice, and Men: Evolutionarily Conserved Tissue Damage Responses and Aging
Neves, J., Demaria, M., Campisi, J., & Jasper, H. (2015) · Developmental Cell · doi:10.1016/j.devcel.2014.11.028 · Cited by 118
“Senescent cells, both mouse and human, also stimulate the growth of neighboring cells by secreting SASP factors, some of which are potent mitogens (Coppé et al., 2010b; Coppé et al., 2008).”
BackgroundMethodInfluentialSelf-citationGaikwad, S., Senapati, S., Haque, M. A., & Kayed, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13490 · Cited by 117
Shivshankar, P., Boyd, A. R., Le Saux, C. J., Yeh, I., & Orihuela, C. J. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00720.x · Cited by 117
“Likewise, they were consistent with the reported SASP profile for senescent HeLa cells (Coppe et al. 2008), and that observed herein for senescent lung epithelial cells.”
ResultCellular senescence: a promising strategy for cancer therapy
Lee, S., & Lee, J.-S. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.294 · Cited by 115
Cellular senescence: Neither irreversible nor reversible
Reimann, M., Lee, S., & Schmitt, C. A. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232136 · Cited by 134
Pathologies Associated with the p53 Response
Gudkov, A. V., & Komarova, E. A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001180 · Cited by 115
“Gradual accumulation of senescent cells characterized by the so-called “pathological secretion phenotype” is considered one of the important systemic pathological alterations accompanying and possibly contributing to aging (Coppe et al. 2008).”
BackgroundCancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment
Wang, S., Prizment, A. E., Thyagarajan, B., & Blaes, A. H. (2021) · Cancers · doi:10.3390/cancers13030427 · Cited by 130
Immune Checkpoint Inhibitors in Real‐World Treatment of Older Adults with Non–Small Cell Lung Cancer
Muchnik, E., Loh, K. P., Strawderman, M. S., Magnuson, A. M., Mohile, S. G., Estrah, V., & Maggiore, R. J. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15750 · Cited by 122
Lunyak, V. V., Amaro-Ortiz, A., & Gaur, M. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00220 · Cited by 114
“Although initially described in fibroblasts (Coppe et al., 2008; Rodier et al., 2009) as a tumor preventive mechanism, SMS is not restricted to the fibroblast.”
BackgroundInfluentialSun, Y., Zhu, D., Chen, F., Qian, M., Wei, H., Chen, W., & Xu, J. (2016) · Oncogene · doi:10.1038/onc.2015.494 · Cited by 116
“16,17 Further, enhanced NF-κ B transcriptional activity and IL-6/IL-8 secretion are among the typical markers of the secretory phenotype formed in DNA damage settings.”
Self-citationRetractedType 2 diabetes is associated with the accumulation of senescent T cells
Lau, E. Y. M., Carroll, E. C., Callender, L. A., Hood, G. A., Berryman, V, Pattrick, M., Finer, S., Hitman, G. A., Ackland, G. L., & Henson, S. M. (2019) · Clinical and Experimental Immunology · doi:10.1111/cei.13344 · Cited by 116
Oncogene-induced senescence: From biology to therapy
Zhu, H., Blake, S., Kusuma, F. K., Pearson, R. B., Kang, J., & Chan, K. T. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111229 · Cited by 116
Bertolo, A., Baur, M., Guerrero, J., Pötzel, T., & Stoyanov, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-38546-2 · Cited by 115
The roles of osteocytes in alveolar bone destruction in periodontitis
Huang, X., Xie, M., Xie, Y., Feng, M., Lu, X., Li, X., & Chen, L. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02664-7 · Cited by 134
“SASP, which is comprised of a variety of secretory proteins, including inflammatory cytokines, chemokines, extracellular matrix remodeling factors, and growth factors, is an important characteristic of senescent cells and has benefits, such as tumor suppression [84], but typically, it promotes chronic inflammation and…”
BackgroundLiu, X., Hoft, D. F., & Peng, G. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133679 · Cited by 126
“Mechanistically, Tregs exhibit heightened glucose uptake, increased glycolysis, and accelerated glucose consumption, which reduce glucose available In contrast to the functional defects in antitumor immunity, senescent T cells are metabolically active and have a unique SASP, which influences both immune cells and tumo…”
BackgroundInfluentialThapa, R. K., Nguyen, H. T., Jeong, J.-H., Kim, J. R., Choi, H.-G., Yong, C. S., & Kim, J. O. (2017) · Scientific Reports · doi:10.1038/srep43299 · Cited by 115
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.